Mikko M.
- Country
- Finland
- Department
- Department of Oncology
Research Overview
- Apixaban for Venous Thromboembolism Prophylaxis During Neoadjuvant Therapy in Muscle‑Invasive Bladder Cancer: International Randomized Controlled Trial
- Phase 3 Randomized Trial of Neoadjuvant Chemotherapy with Nivolumab and BMS-986205 in Muscle-Invasive Bladder Cancer
- A Phase 3 Randomized, Open-label Study of Opevesostat Tosylate Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Data & Insights
Has run more than one trial at 19 of 110 partner sites.
Specializations
Urological Oncology
The investigator specializes in treating advanced urological cancers, with particular focus on muscle-invasive bladder cancer and metastatic castration-resistant prostate cancer.
- Bladder Cancer Management
- Prostate Cancer Therapeutics
- Genitourinary Malignancies
Their expertise extends to innovative therapeutic approaches in treating aggressive urological cancers.
Immunotherapy Applications
The investigator focuses on implementing immunotherapeutic approaches in urological cancers, particularly exploring the integration of nivolumab in treatment protocols.
- Combined Immunotherapy Strategies
- Neoadjuvant Treatment Protocols
- Post-surgical Therapeutic Approaches
Their work encompasses both pre-surgical and maintenance treatment strategies in oncology.
Advanced Cancer Therapeutics
The investigator evaluates novel therapeutic agents for treating advanced urological malignancies, including assessment of new compounds against established treatments.
- Novel Drug Development
- Comparative Treatment Efficacy
- Treatment Resistance Management
Their research includes evaluation of survival outcomes and disease progression in advanced cancer cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.